PortalPublikationenKRAS mutations in codon 12 or 13 are associated with worse p...

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma

Standard

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. / Sinn, Bruno V; Striefler, Jana K; Rudl, Marc A; Lehmann, Annika; Bahra, Marcus; Denkert, Carsten; Sinn, Marianne; Stieler, Jens; Klauschen, Frederick; Budczies, Jan; Weichert, Wilko; Stenzinger, Albrecht; Kamphues, Carsten; Dietel, Manfred; Riess, Hanno.

in: PANCREAS, Jahrgang 43, Nr. 4, 05.2014, S. 578-83.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sinn, BV, Striefler, JK, Rudl, MA, Lehmann, A, Bahra, M, Denkert, C, Sinn, M, Stieler, J, Klauschen, F, Budczies, J, Weichert, W, Stenzinger, A, Kamphues, C, Dietel, M & Riess, H 2014, 'KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma', PANCREAS, Jg. 43, Nr. 4, S. 578-83. https://doi.org/10.1097/MPA.0000000000000077

APA

Sinn, B. V., Striefler, J. K., Rudl, M. A., Lehmann, A., Bahra, M., Denkert, C., Sinn, M., Stieler, J., Klauschen, F., Budczies, J., Weichert, W., Stenzinger, A., Kamphues, C., Dietel, M., & Riess, H. (2014). KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. PANCREAS, 43(4), 578-83. https://doi.org/10.1097/MPA.0000000000000077

Vancouver

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C et al. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. PANCREAS. 2014 Mai;43(4):578-83. https://doi.org/10.1097/MPA.0000000000000077

Bibtex

@article{7d894fcaed38450a9403ac100f6806c2,
title = "KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma",
abstract = "OBJECTIVE: Mutations in the KRAS and P53 genes belong to the most frequently observed genetic alterations in pancreatic ductal adenocarcinoma. The aim of this study was to examine the frequency and prognostic impact of KRAS mutations. In addition, we attempted to define molecular subgroups with distinct biologic behavior by combination of KRAS sequencing data with p53 protein expression data.METHODS: KRAS mutational analyses were performed in a study group of 153 patients by Sanger sequencing. Immunohistochemistry for p53 was performed on tissue microarrays.RESULTS: KRAS mutations in codon 12 or 13 were found in 68% of cases. Nuclear staining for p53 was detectable in 110 (68%) of 162 evaluable cases. We found no correlation between KRAS mutational status and p53 expression. KRAS mutational status but not p53 immunohistochemistry was an independent prognostic factor in the study group (P = 0.02). In a stratified analysis according to KRAS mutational status, p53 expression failed to define prognostic groups beyond the impact of KRAS mutational status.CONCLUSIONS: Our results support the crucial role of KRAS mutational status in pancreatic cancer biology. KRAS mutational status may serve as a prognostic marker. However, its predictive role for targeted therapies remains to be evaluated.",
keywords = "Aged, Biomarkers, Tumor/analysis, Carcinoma, Pancreatic Ductal/chemistry, Codon, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Pancreatic Neoplasms/chemistry, Phenotype, Predictive Value of Tests, Prognosis, Proto-Oncogene Proteins/genetics, Proto-Oncogene Proteins p21(ras), Risk Factors, Tumor Suppressor Protein p53/analysis, ras Proteins/genetics",
author = "Sinn, {Bruno V} and Striefler, {Jana K} and Rudl, {Marc A} and Annika Lehmann and Marcus Bahra and Carsten Denkert and Marianne Sinn and Jens Stieler and Frederick Klauschen and Jan Budczies and Wilko Weichert and Albrecht Stenzinger and Carsten Kamphues and Manfred Dietel and Hanno Riess",
year = "2014",
month = may,
doi = "10.1097/MPA.0000000000000077",
language = "English",
volume = "43",
pages = "578--83",
journal = "PANCREAS",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma

AU - Sinn, Bruno V

AU - Striefler, Jana K

AU - Rudl, Marc A

AU - Lehmann, Annika

AU - Bahra, Marcus

AU - Denkert, Carsten

AU - Sinn, Marianne

AU - Stieler, Jens

AU - Klauschen, Frederick

AU - Budczies, Jan

AU - Weichert, Wilko

AU - Stenzinger, Albrecht

AU - Kamphues, Carsten

AU - Dietel, Manfred

AU - Riess, Hanno

PY - 2014/5

Y1 - 2014/5

N2 - OBJECTIVE: Mutations in the KRAS and P53 genes belong to the most frequently observed genetic alterations in pancreatic ductal adenocarcinoma. The aim of this study was to examine the frequency and prognostic impact of KRAS mutations. In addition, we attempted to define molecular subgroups with distinct biologic behavior by combination of KRAS sequencing data with p53 protein expression data.METHODS: KRAS mutational analyses were performed in a study group of 153 patients by Sanger sequencing. Immunohistochemistry for p53 was performed on tissue microarrays.RESULTS: KRAS mutations in codon 12 or 13 were found in 68% of cases. Nuclear staining for p53 was detectable in 110 (68%) of 162 evaluable cases. We found no correlation between KRAS mutational status and p53 expression. KRAS mutational status but not p53 immunohistochemistry was an independent prognostic factor in the study group (P = 0.02). In a stratified analysis according to KRAS mutational status, p53 expression failed to define prognostic groups beyond the impact of KRAS mutational status.CONCLUSIONS: Our results support the crucial role of KRAS mutational status in pancreatic cancer biology. KRAS mutational status may serve as a prognostic marker. However, its predictive role for targeted therapies remains to be evaluated.

AB - OBJECTIVE: Mutations in the KRAS and P53 genes belong to the most frequently observed genetic alterations in pancreatic ductal adenocarcinoma. The aim of this study was to examine the frequency and prognostic impact of KRAS mutations. In addition, we attempted to define molecular subgroups with distinct biologic behavior by combination of KRAS sequencing data with p53 protein expression data.METHODS: KRAS mutational analyses were performed in a study group of 153 patients by Sanger sequencing. Immunohistochemistry for p53 was performed on tissue microarrays.RESULTS: KRAS mutations in codon 12 or 13 were found in 68% of cases. Nuclear staining for p53 was detectable in 110 (68%) of 162 evaluable cases. We found no correlation between KRAS mutational status and p53 expression. KRAS mutational status but not p53 immunohistochemistry was an independent prognostic factor in the study group (P = 0.02). In a stratified analysis according to KRAS mutational status, p53 expression failed to define prognostic groups beyond the impact of KRAS mutational status.CONCLUSIONS: Our results support the crucial role of KRAS mutational status in pancreatic cancer biology. KRAS mutational status may serve as a prognostic marker. However, its predictive role for targeted therapies remains to be evaluated.

KW - Aged

KW - Biomarkers, Tumor/analysis

KW - Carcinoma, Pancreatic Ductal/chemistry

KW - Codon

KW - DNA Mutational Analysis

KW - Female

KW - Genetic Predisposition to Disease

KW - Humans

KW - Immunohistochemistry

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Mutation

KW - Pancreatic Neoplasms/chemistry

KW - Phenotype

KW - Predictive Value of Tests

KW - Prognosis

KW - Proto-Oncogene Proteins/genetics

KW - Proto-Oncogene Proteins p21(ras)

KW - Risk Factors

KW - Tumor Suppressor Protein p53/analysis

KW - ras Proteins/genetics

U2 - 10.1097/MPA.0000000000000077

DO - 10.1097/MPA.0000000000000077

M3 - SCORING: Journal article

C2 - 24681874

VL - 43

SP - 578

EP - 583

JO - PANCREAS

JF - PANCREAS

SN - 0885-3177

IS - 4

ER -